Table 2 5-year overall- and disease free survival rates depending on subgroups of prognostic factors (* p-values of log-rank tests comparing survival times between subgroups)
5-year OS rate | 5-year DFS rate | |||||
|---|---|---|---|---|---|---|
% | p* | % | p* | |||
All patients n (%) | 212 (100 %) | 53 | 46 | |||
Sequencing of chemo- and radiotherapy n (%) | SEQ | 86 (40.6) | 53.2 | 0.04 | 56 | 0.03 |
SW | 70 (33) | 38.1 | 32 | |||
SIM | 56 (26.4) | 64.2 | 50 | |||
Age n (%) | age ≤ 50 | 41 (19.3) | 59.4 | 0.9 | 52.2 | 0.6 |
age > 50 | 171 (80.7) | 52.2 | 45.3 | |||
histological type n (%) | ductal-invasiv | 158 (74.5) | 54.2 | 0.6 | 47.8 | 0.6 |
ductal-lobular | 35 (16.5) | 47.6 | 45.2 | |||
other | 19 (9) | 46.8 | 0 | |||
pT n (%) | pT1 | 33 (15.6) | 70.6 | 0.06 | 70.8 | 0.03 |
pT2 | 90 (42.5) | 59.8 | 44.4 | |||
pT3 | 41 (19.3) | 54.2 | 45.1 | |||
pT4 | 48 (22.6) | 31.4 | 36.8 | |||
pN n (%) | pN0 | 48 (22.6) | 65.7 | 0.1 | 52.2 | 0.1 |
pN1 | 35 (16.5) | 53.8 | 53.4 | |||
pN2-3 | 129 (60.8) | 48.5 | 42.1 | |||
LVI n (%) | yes | 77 (36.3) | 40.4 | 0.01 | 34.9 | 0.001 |
no | 135 (63.7) | 59.4 | 52.9 | |||
G n (%) | G1 | 5 (2.4) | 33.1 | 0.04 | 53.3 | 0.3 |
G2 | 89 (42) | 63.2 | 49.5 | |||
G3 | 118 (55.7) | 46.2 | 44.6 | |||
ECS n (%) | yes | 110 (51.9) | 44.8 | 0.04 | 40.2 | 0.01 |
no | 102 (48.1) | 61.8 | 52.2 | |||
Receptor (ER and/or PR) n (%) | positive | 158 (74.5) | 56.7 | 0.07 | 48.1 | 0.2 |
negative | 54 (25.5) | 41.3 | 40.0 | |||
R n (%) | R0 | 197 (92.9) | 53.3 | 0.8 | 47.3 | 0.04 |
R+ | 15 (7.1) | 56.7 | 35.0 | |||
V n (%) | yes | 194 (91.5) | 0 | 0.03 | 0 | 0.002 |
no | 18 (8.5) | 55.0 | 48.3 | |||
RT region n (%) parasternal fields (in 28.3% created) not separately considered | THW +SIA | 148 (69.8) | 52.2 | 0.4 | 51.9 | 0.4 |
THW alone | 17 (8) | 72.8 | 0 | |||
SIA alone | 47 (22.2) | 50.6 | 36.6 | |||